Skip to main content
. 2015 Dec 9;12:41. doi: 10.1186/s12981-015-0080-9

Table 1.

HIV patients stable on ART retain high titres of CMV reactive antibodies, with NK cell phenotypes and function affected by HIV and CMV status

HIV patients CMV+ controls CMV− controls A vs B A vs C B vs C
A B C P b P b P b
n 20 16 9
Male:female 19:1 14:2 9:0 0.57c 1 0.52
Age (years) 62 (57–68)a 60 (57–62) 55 (53–59) 0.19 0.04 0.11
CMV lysate IgG (AU/ml) 94 (56–240) 20 (10–35) 0.9 (0.6–1.0) <0.0001 <0.0001 <0.0001
CMV gB IgG (AU/ml) 127 (90–172) 45 (27–55) 1.9 (1.1–2.8) <0.0001 <0.0001 0.0001
CMV IE–1 IgG (AU/ml) 49 (21–166) 8 (4.3–180) 2.6 (2.0–3.7) <0.0001 <0.0001 0.0017
CMV lysate IFNγe 227 (16–700) 157 (13–617) 0 (0–0.5) 0.16 <0.0001 <0.0001
NK cells (% lymphocytes) 12 (8.3–18) 17 (11–20) 17 (12–22) 0.09 0.07 0.76
CD8 T-cells (% lymphocytes) 39 (19–48) 17 (7–23) 13 (10–19) 0.0007 0.001 0.71
CD56hi/CD56lo ratio × 100 7.2 (3.5–18) 7 (2.5–9.8) 12 (9.0–26) 0.51 0.01 0.06
IFNγ+ (% NK cells)d 0.2 (0.1–0.32) 0.1 (0.1–0.38) 0.4 (0.15–0.55) 0.93 0.19 0.17
IFNγ+ (% NK cells) + K562 0.8 (0.3–1.10) 1.7 (1.0–2.6) 1 (0.65–2.75) 0.006 0.21 0.4
CD56hiIFNγlo (% NK cells)d 0.36 (0.07–1.3) 1.1 (0.48–1.6) 0.4 (0.16–0.97) 0.08 0.96 0.12
CD107a+ (% NK cells)d 6.3 (2.6–8.6) 6.2 (4.6–7.9) 3.0 (2.2–6.0) 0.86 0.16 0.03
CD107a+ (% NK cells) + K562 11 (6.3–14) 16 (9.8–17) 8.4 (6.1–11) 0.03 0.48 0.006
LIR–1 MFI (NK cells) 554 (419–706) 524 (351–774) 301 (270–734) 0.82 0.27 0.17
LIR–1 MFI (CD8 T cells) 494 (385–679) 526 (429–852) 374 (283–807) 0.3 0.07 0.15
CD57+ (%NK cells) 77 (59–83) 64 (54–66) 63 (59–65) 0.02 0.09 0.98
CD56lo perforinhi (% NK cells)d 85 (76–90) 83 (77–89) 79 (70–87) 0.77 0.29 0.25
CD56hi perforinlo (% NK cells)d 3.0 (1.0–5.9) 3.1 (1.7–5.3) 5.2 (2.9–5.3) 0.88 0.07 0.08

aMedian (interquartile range)

bMann–Whitney tests (continuous data), P ≤ 0.05 (bold), P > 0.05–0.1 (italics)

cFisher’s exact test (categorical data)

dCultured without K562 cells

eIFNγ spots per 2 × 106 cells